KOD News and Press, Kodiak Sciences Inc From 07/07/20

PALO ALTO, Calif. , July 7, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that new data from the ongoing Phase 1b study of KSI-301...

Market Pulse The question of whether it's a new bull market rally or just an intermittent bear market rally doomed to end later this year will most likely be decided late in the third quarter or during the fourth quarter when enough evidence on the durability of the recovery pace is forthcom...

Image source: The Motley Fool. Kodiak Sciences Inc.   (NASDAQ: KOD) Q1 2020 Earnings Call May 12, 2020 , 4:30 p.m. ET Operator Continue reading

Kodiak Sciences Inc. (KOD) Q1 2020 Earnings Conference Call May 12, 2020 4:30 PM ET Company Participants John Borgeson - Chief Financial Officer Victor Perlroth - Chairman and Chief Executive Officer Jason Ehrlich - Chief Medical Officer and Chief Development Officer Conferenc...

The following slide deck was published by Kodiak Sciences Inc. in conjunction with their 2020 Q1 earnings Read more ...

Biotech Pulse Source: COVID-19 image by Getty Images; edits by PrudentBiotech.com It has taken a pandemic for biotechs to take flight towards their all-time high. One of the first industry groups to recover from the virus-related selloff and be neutral for the year, biotech indexes hav...

PALO ALTO, Calif. , May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the virtual Bank of America Mer...

Kodiak Sciences (NASDAQ: KOD ): Q1 GAAP EPS of -$0.54 misses by $0.04 . Cash, cash equivalents and marketable securities of $430.39M Press Release More news on: Kodiak Sciences Inc., Earnings news and commentary, Healthcare stocks news,

PALO ALTO, Calif. , May 11, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the firs...

PALO ALTO, Calif. , May 8, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that it will host a business highlights webcast on Tuesday...